• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    3/25/24 5:32:19 PM ET
    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGRX alert in real time by email

    Gainers

    • Stoke Therapeutics (NASDAQ:STOK) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings report came out today.
    • OpGen (NASDAQ:OPGN) shares moved upwards by 66.61% to $0.79. The market value of their outstanding shares is at $7.9 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock rose 11.62% to $1.92. The company's market cap stands at $7.0 million.
    • Vaxxinity (NASDAQ:VAXX) shares moved upwards by 7.99% to $0.72. The company's market cap stands at $90.8 million.
    • Unity Biotechnology (NASDAQ:UBX) stock rose 7.39% to $1.7. The market value of their outstanding shares is at $28.4 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock increased by 6.87% to $0.7. The market value of their outstanding shares is at $34.2 million.

    Losers

    • Agile Therapeutics (NASDAQ:AGRX) shares declined by 54.7% to $0.27 during Monday's after-market session.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock decreased by 54.53% to $0.45. The market value of their outstanding shares is at $1.6 million.
    • Portage Biotech (NASDAQ:PRTG) stock declined by 6.73% to $0.48. The market value of their outstanding shares is at $9.4 million.
    • Omeros (NASDAQ:OMER) shares decreased by 6.69% to $3.21. The company's market cap stands at $201.7 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares decreased by 6.46% to $1.73. The company's market cap stands at $24.2 million.
    • Regenxbio (NASDAQ:RGNX) stock decreased by 5.15% to $20.48. The company's market cap stands at $1.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $BCLI
    $BIMI
    $NBSE

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    REGENXBIO Inc.
    $RGNX
    1/28/2026$37.00Overweight
    Barclays
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Omeros Corporation
    $OMER
    6/10/2025$9.00Buy
    H.C. Wainwright
    Unity Biotechnology Inc.
    $UBX
    5/27/2025$2.00Buy → Neutral
    H.C. Wainwright
    Unity Biotechnology Inc.
    $UBX
    5/16/2025$6.00 → $1.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $33.96 per share, which is equal to the closing price of Stok

    3/17/26 5:12:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

    Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 year, including participants aged 8+Cardiac MRI data for pivotal dose patients demonstrated stability at 1 yearFavorable safety profile continued with no serious adverse events or adverse events of special interest observed in Phase I/II studyNew data from multiple measures supported liver safety in pivotal patientsPivotal topline data expected Q2 2026ROCKVILLE, Md., March 11, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced new positive interim data from the Phase I/II AFFINITY D

    3/11/26 11:45:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on REGENXBIO with a new price target

    Barclays resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $37.00

    1/28/26 7:18:39 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    12/10/24 12:32:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    10/8/24 6:51:09 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    SEC Filings

    View All

    SEC Form S-3ASR filed by Stoke Therapeutics Inc.

    S-3ASR - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/18/26 4:06:22 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Stoke Therapeutics Inc.

    S-8 - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/16/26 5:28:54 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Stoke Therapeutics Inc.

    10-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/16/26 4:15:29 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:20:47 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Leadership Updates

    Live Leadership Updates

    View All

    UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

    SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.

    3/10/25 8:00:00 AM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

    SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo

    1/6/25 8:00:00 AM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

    WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distin

    1/6/25 5:00:49 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology comp

    2/25/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $BCLI
    $BIMI
    $NBSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/14/24 9:00:57 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unity Biotechnology Inc.

    SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

    11/14/24 4:35:22 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care